Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody drug conjugate

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

- PMLiVE

New guide to improve cancer control published in EU

Outlines recommendations to boost quality of life and reduce financial burden

- PMLiVE

Winning the war against cancer

Dr Josep Figueras on survival, access to treatments and the need for good data in oncology

- PMLiVE

Seattle Genetics signs $2bn deal for Immunomedics’ cancer drug

Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end

- PMLiVE

Dr Reddy’s brings its generics portfolio to France

Continues the European roll-out of its oncology and anti-infective products

- PMLiVE

AbbVie weak on new drug sales, but Humira stays strong

World’s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

- PMLiVE

Two new hepatitis C therapies fast-tracked in Europe

EMA speeds review process for Gilead and AbbVie treatments

- PMLiVE

AZ drug discovery robot programed for cancer research

Firm says NiCoLA-B is world's most advanced drug discovery robot

- PMLiVE

Merck forges cancer-focused big data alliance with Palantir

Plans to develop a collaborative analytics platform to accelerate research and improve outcomes

- PMLiVE

Ashley Communications celebrates 20 years of medical communications

Looks forward with new business wins, including AbbVie and Merck & Co accounts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links